Rockwell Medical (NASDAQ:RMTI) announced its quarterly earnings data on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02, Fidelity Earnings reports. Rockwell Medical had a negative net margin of 52.11% and a negative return on equity of 143.68%. The firm had revenue of $15.41 million for the quarter, compared to analysts’ expectations of $15.40 million.
RMTI traded up $0.16 during mid-day trading on Tuesday, hitting $2.07. The stock had a trading volume of 11,463 shares, compared to its average volume of 284,010. The stock’s fifty day simple moving average is $2.49 and its 200-day simple moving average is $3.26. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.25 and a quick ratio of 2.99. The firm has a market capitalization of $118.39 million, a price-to-earnings ratio of -4.40 and a beta of 1.45. Rockwell Medical has a 1-year low of $1.81 and a 1-year high of $6.88.
Several equities research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Rockwell Medical in a report on Monday, October 28th. ValuEngine upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Piper Jaffray Companies cut their target price on shares of Rockwell Medical to $6.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Zacks Investment Research upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a report on Friday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $8.06.
Rockwell Medical, Inc operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.
Read More: High-Yield Dividend Stocks
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.